Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma

A National Cancer Data Base analysis

Priscilla K. Stumpf, Arya Amini, Bernard L. Jones, Matthew Koshy, David J. Sher, Christopher H. Lieu, Tracey E. Schefter, Karyn A. Goodman, Chad G. Rusthoven

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND: For patients with resectable gastric adenocarcinoma, perioperative chemotherapy and adjuvant chemoradiotherapy (CRT) are considered standard options. In the current study, the authors used the National Cancer Data Base to compare overall survival (OS) between these regimens. METHODS: Patients who underwent gastrectomy for nonmetastatic gastric adenocarcinoma from 2004 through 2012 were divided into those treated with perioperative chemotherapy without RT versus those treated with adjuvant CRT. Survival was estimated and compared using univariate and multivariate models adjusted for patient and tumor characteristics, surgical margin status, and the number of lymph nodes examined. Subset analyses were performed for factors chosen a priori, and potential interactions between treatment and covariates were assessed. RESULTS: A total of 3656 eligible patients were identified, 52% of whom underwent perioperative chemotherapy and 48% of whom received postoperative CRT. The median follow-up was 47 months, and the median age of the patients was 62 years. Analysis of the entire cohort demonstrated improved OS with adjuvant RT on both univariate (median of 51 months vs 42 months; P =.013) and multivariate (hazard ratio, 0.874; 95% confidence interval, 0.790-0.967 [P =.009]) analyses. Propensity score-matched analysis also demonstrated improved OS with adjuvant RT (median of 49 months vs 39 months; P =.033). On subset analysis, a significant interaction was observed between the survival impact of adjuvant RT and surgical margins, with a greater benefit of RT noted among patients with surgical margin-positive disease (hazard ratio with RT: 0.650 vs 0.952; P for interaction <.001). CONCLUSIONS: In this National Cancer Data Base analysis, the use of adjuvant RT in addition to chemotherapy was associated with a significant OS advantage for patients with resected gastric cancer. The survival advantage observed with adjuvant CRT was most pronounced among patients with positive surgical margins. Cancer 2017;123:3402-9.

Original languageEnglish (US)
Pages (from-to)3402-3409
Number of pages8
JournalCancer
Volume123
Issue number17
DOIs
StatePublished - Sep 1 2017

Fingerprint

Adjuvant Radiotherapy
Stomach
Adenocarcinoma
Databases
Survival
Adjuvant Chemoradiotherapy
Neoplasms
Drug Therapy
Propensity Score
Chemoradiotherapy
Gastrectomy
Stomach Neoplasms
Cohort Studies
Lymph Nodes
Confidence Intervals
Margins of Excision

Keywords

  • adenocarcinoma
  • chemoradiotherapy (CRT)
  • conformal radiotherapy
  • gastrectomy
  • stomach

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma : A National Cancer Data Base analysis. / Stumpf, Priscilla K.; Amini, Arya; Jones, Bernard L.; Koshy, Matthew; Sher, David J.; Lieu, Christopher H.; Schefter, Tracey E.; Goodman, Karyn A.; Rusthoven, Chad G.

In: Cancer, Vol. 123, No. 17, 01.09.2017, p. 3402-3409.

Research output: Contribution to journalArticle

Stumpf, PK, Amini, A, Jones, BL, Koshy, M, Sher, DJ, Lieu, CH, Schefter, TE, Goodman, KA & Rusthoven, CG 2017, 'Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis', Cancer, vol. 123, no. 17, pp. 3402-3409. https://doi.org/10.1002/cncr.30748
Stumpf, Priscilla K. ; Amini, Arya ; Jones, Bernard L. ; Koshy, Matthew ; Sher, David J. ; Lieu, Christopher H. ; Schefter, Tracey E. ; Goodman, Karyn A. ; Rusthoven, Chad G. / Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma : A National Cancer Data Base analysis. In: Cancer. 2017 ; Vol. 123, No. 17. pp. 3402-3409.
@article{122ff94e825b47069a1d49257e10400a,
title = "Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis",
abstract = "BACKGROUND: For patients with resectable gastric adenocarcinoma, perioperative chemotherapy and adjuvant chemoradiotherapy (CRT) are considered standard options. In the current study, the authors used the National Cancer Data Base to compare overall survival (OS) between these regimens. METHODS: Patients who underwent gastrectomy for nonmetastatic gastric adenocarcinoma from 2004 through 2012 were divided into those treated with perioperative chemotherapy without RT versus those treated with adjuvant CRT. Survival was estimated and compared using univariate and multivariate models adjusted for patient and tumor characteristics, surgical margin status, and the number of lymph nodes examined. Subset analyses were performed for factors chosen a priori, and potential interactions between treatment and covariates were assessed. RESULTS: A total of 3656 eligible patients were identified, 52{\%} of whom underwent perioperative chemotherapy and 48{\%} of whom received postoperative CRT. The median follow-up was 47 months, and the median age of the patients was 62 years. Analysis of the entire cohort demonstrated improved OS with adjuvant RT on both univariate (median of 51 months vs 42 months; P =.013) and multivariate (hazard ratio, 0.874; 95{\%} confidence interval, 0.790-0.967 [P =.009]) analyses. Propensity score-matched analysis also demonstrated improved OS with adjuvant RT (median of 49 months vs 39 months; P =.033). On subset analysis, a significant interaction was observed between the survival impact of adjuvant RT and surgical margins, with a greater benefit of RT noted among patients with surgical margin-positive disease (hazard ratio with RT: 0.650 vs 0.952; P for interaction <.001). CONCLUSIONS: In this National Cancer Data Base analysis, the use of adjuvant RT in addition to chemotherapy was associated with a significant OS advantage for patients with resected gastric cancer. The survival advantage observed with adjuvant CRT was most pronounced among patients with positive surgical margins. Cancer 2017;123:3402-9.",
keywords = "adenocarcinoma, chemoradiotherapy (CRT), conformal radiotherapy, gastrectomy, stomach",
author = "Stumpf, {Priscilla K.} and Arya Amini and Jones, {Bernard L.} and Matthew Koshy and Sher, {David J.} and Lieu, {Christopher H.} and Schefter, {Tracey E.} and Goodman, {Karyn A.} and Rusthoven, {Chad G.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1002/cncr.30748",
language = "English (US)",
volume = "123",
pages = "3402--3409",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "17",

}

TY - JOUR

T1 - Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma

T2 - A National Cancer Data Base analysis

AU - Stumpf, Priscilla K.

AU - Amini, Arya

AU - Jones, Bernard L.

AU - Koshy, Matthew

AU - Sher, David J.

AU - Lieu, Christopher H.

AU - Schefter, Tracey E.

AU - Goodman, Karyn A.

AU - Rusthoven, Chad G.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - BACKGROUND: For patients with resectable gastric adenocarcinoma, perioperative chemotherapy and adjuvant chemoradiotherapy (CRT) are considered standard options. In the current study, the authors used the National Cancer Data Base to compare overall survival (OS) between these regimens. METHODS: Patients who underwent gastrectomy for nonmetastatic gastric adenocarcinoma from 2004 through 2012 were divided into those treated with perioperative chemotherapy without RT versus those treated with adjuvant CRT. Survival was estimated and compared using univariate and multivariate models adjusted for patient and tumor characteristics, surgical margin status, and the number of lymph nodes examined. Subset analyses were performed for factors chosen a priori, and potential interactions between treatment and covariates were assessed. RESULTS: A total of 3656 eligible patients were identified, 52% of whom underwent perioperative chemotherapy and 48% of whom received postoperative CRT. The median follow-up was 47 months, and the median age of the patients was 62 years. Analysis of the entire cohort demonstrated improved OS with adjuvant RT on both univariate (median of 51 months vs 42 months; P =.013) and multivariate (hazard ratio, 0.874; 95% confidence interval, 0.790-0.967 [P =.009]) analyses. Propensity score-matched analysis also demonstrated improved OS with adjuvant RT (median of 49 months vs 39 months; P =.033). On subset analysis, a significant interaction was observed between the survival impact of adjuvant RT and surgical margins, with a greater benefit of RT noted among patients with surgical margin-positive disease (hazard ratio with RT: 0.650 vs 0.952; P for interaction <.001). CONCLUSIONS: In this National Cancer Data Base analysis, the use of adjuvant RT in addition to chemotherapy was associated with a significant OS advantage for patients with resected gastric cancer. The survival advantage observed with adjuvant CRT was most pronounced among patients with positive surgical margins. Cancer 2017;123:3402-9.

AB - BACKGROUND: For patients with resectable gastric adenocarcinoma, perioperative chemotherapy and adjuvant chemoradiotherapy (CRT) are considered standard options. In the current study, the authors used the National Cancer Data Base to compare overall survival (OS) between these regimens. METHODS: Patients who underwent gastrectomy for nonmetastatic gastric adenocarcinoma from 2004 through 2012 were divided into those treated with perioperative chemotherapy without RT versus those treated with adjuvant CRT. Survival was estimated and compared using univariate and multivariate models adjusted for patient and tumor characteristics, surgical margin status, and the number of lymph nodes examined. Subset analyses were performed for factors chosen a priori, and potential interactions between treatment and covariates were assessed. RESULTS: A total of 3656 eligible patients were identified, 52% of whom underwent perioperative chemotherapy and 48% of whom received postoperative CRT. The median follow-up was 47 months, and the median age of the patients was 62 years. Analysis of the entire cohort demonstrated improved OS with adjuvant RT on both univariate (median of 51 months vs 42 months; P =.013) and multivariate (hazard ratio, 0.874; 95% confidence interval, 0.790-0.967 [P =.009]) analyses. Propensity score-matched analysis also demonstrated improved OS with adjuvant RT (median of 49 months vs 39 months; P =.033). On subset analysis, a significant interaction was observed between the survival impact of adjuvant RT and surgical margins, with a greater benefit of RT noted among patients with surgical margin-positive disease (hazard ratio with RT: 0.650 vs 0.952; P for interaction <.001). CONCLUSIONS: In this National Cancer Data Base analysis, the use of adjuvant RT in addition to chemotherapy was associated with a significant OS advantage for patients with resected gastric cancer. The survival advantage observed with adjuvant CRT was most pronounced among patients with positive surgical margins. Cancer 2017;123:3402-9.

KW - adenocarcinoma

KW - chemoradiotherapy (CRT)

KW - conformal radiotherapy

KW - gastrectomy

KW - stomach

UR - http://www.scopus.com/inward/record.url?scp=85019628329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019628329&partnerID=8YFLogxK

U2 - 10.1002/cncr.30748

DO - 10.1002/cncr.30748

M3 - Article

VL - 123

SP - 3402

EP - 3409

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 17

ER -